+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review



Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review



Annals of Surgery 259(2): 360-368



To clarify the recurrence pattern after resection of main duct intraductal papillary mucinous neoplasms (MD-IPMNs) using molecular analyses and determine the most adequate treatment strategy. The most appropriate resection line for MD-IPMNs remains an unresolved issue. Medical records of 56 patients with pancreatectomy were retrospectively reviewed. Histological subtypes and Kras/GNAS mutations were assessed in patients with recurrence in the remnant pancreas. Forty-nine patients underwent partial pancreatectomy and 7 underwent total pancreatectomy. Thirty-six patients (64%) had malignant MD-IPMNs. Recurrence was observed in 7 of 49 patients (14%), including 6 with malignant IPMNs and 1 with pancreatic ductal adenocarcinoma, all of whom underwent remnant pancreatectomy. The cumulative disease-specific survival rate of patients with pancreatic recurrence was greater than that of patients with extrapancreatic recurrence (P < 0.001). Although the pancreatic margin status at the initial operation did not affect the pancreatic recurrence rate, all 4 recurrent IPMNs examined had histological subtypes and Kras/GNAS mutations identical to those of the initial lesions. Four patients experienced recurrence in the remnant pancreas or systemic recurrence after resection of high-grade dysplasia of MD-IPMN. Three of the 56 patients had concomitant pancreatic ductal adenocarcinomas and MD-IPMNs. One-step total pancreatectomy can be avoided, and remnant total pancreatectomy would lead to favorable outcomes even in patients with pancreatic recurrence, some cases of which seem to involve residual lesions. Postoperative surveillance of high-grade dysplasia should be performed as if malignant, and close attention should be paid to the occurrence of concomitant pancreatic ductal adenocarcinomas in patients with MD-IPMNs.

(PDF emailed within 0-6 h: $19.90)

Accession: 056682509

Download citation: RISBibTeXText

PMID: 23989056

DOI: 10.1097/SLA.0b013e3182a690ff


Related references

Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis. Surgery 157(2): 277-284, 2015

Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Journal of the American College of Surgeons 220(2): 243-253, 2015

Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Annals of Surgery 239(5): 678-85; Discussion 685-7, 2004

Lateral spread along the main pancreatic duct in branch-duct intraductal papillary-mucinous neoplasms of the pancreas: usefulness of intraductal ultrasonography for its evaluation. Digestive Endoscopy 23(1): 62-68, 2011

Main-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 239(5): 678-687, 2004

Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. World Journal of Gastrointestinal Surgery 2(10): 342-346, 2010

Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas. World Journal of Gastroenterology 21(9): 2658-2667, 2015

Validation of the 2012 International Consensus Guidelines Using CT and MRI: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 266(6): E51-E52, 2017

Management strategy for multifocal branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 41(7): 1008-1012, 2013

Potential predictors of disease progression for main-duct intraductal papillary mucinous neoplasms of the pancreas. Journal of Gastroenterology and Hepatology 28(11): 1782-1786, 2014

Predictors of malignancy and natural history of main-duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 40(3): 371-375, 2011

Tumor doubling time in two cases of main duct intraductal papillary-mucinous neoplasms of the pancreas. Hepato-Gastroenterology 56(94-95): 1545-1548, 2009

The distribution of atypical epithelium in main-duct type intraductal papillary mucinous neoplasms of the pancreas. Journal of Hepato-Biliary-Pancreatic Sciences 18(2): 241-6; Discussion 246-9, 2011

Should we regard all main duct type intraductal papillary mucinous neoplasms of the pancreas (MD-IPMN) as an indication of surgery? -A retrospective study in 29 patients with MD-IPMN showing mural nodules. Pancreatology 2019, 2019

Proper management and follow-up strategy of branch duct intraductal papillary mucinous neoplasms of the pancreas. Digestive and Liver Disease 44(3): 257-260, 2012